ASCO 2024 - LBA4: The LAURA Study
Ғылым және технология
LBA4 (Ramalingam): Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
Пікірлер